MedTrace Logo

International Trial of the Efficacy and Safety of BCD-100 in Patients With Melanoma

NCT03269565 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2020-09-18

No results posted yet for this study

Summary

An International Multicenter Open-label Randomized Trial of the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) as Monotherapy in Patients with Unresectable/Metastatic Melanoma.

Conditions

Interventions

BIOLOGICAL

BCD-100

Anti-PD-1 monoclonal antibody

Sponsors & Collaborators

  • Biocad

    lead INDUSTRY

Principal Investigators

  • Yulia N Linkova, MD, PhD · Director of Clinical Development Department, BIOCAD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-31
Primary Completion
2018-08-29
Completion
2021-01-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03269565 on ClinicalTrials.gov